Ionis Pharmaceuticals, Inc. vs Arrowhead Pharmaceuticals, Inc.: Annual Revenue Growth Compared

Biotech Revenue Growth: Ionis vs. Arrowhead

__timestampArrowhead Pharmaceuticals, Inc.Ionis Pharmaceuticals, Inc.
Wednesday, January 1, 2014175000214161000
Thursday, January 1, 2015382000283703000
Friday, January 1, 2016158333346620000
Sunday, January 1, 201731407709507666000
Monday, January 1, 201816142321599674000
Tuesday, January 1, 20191687955771123000000
Wednesday, January 1, 202087992066729000000
Friday, January 1, 2021138287000810000000
Saturday, January 1, 2022243231000587000000
Sunday, January 1, 2023240735000787647000
Monday, January 1, 20243551000705138000
Loading chart...

In pursuit of knowledge

A Tale of Two Biotechs: Revenue Growth in Focus

In the competitive world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, Ionis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc. have shown contrasting trajectories. Ionis Pharmaceuticals has consistently outperformed Arrowhead, with its revenue peaking at approximately $1.1 billion in 2019, a remarkable 400% increase from 2014. In contrast, Arrowhead Pharmaceuticals, despite a significant leap in 2022, reaching around $243 million, has experienced more volatility, with revenues fluctuating over the years.

The data reveals that Ionis has maintained a steady upward trend, while Arrowhead's growth has been more erratic, with a notable dip in 2024. This comparison highlights the challenges and opportunities within the biotech sector, where innovation and strategic partnerships can significantly impact financial outcomes.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025